Results 51 to 60 of about 48,810 (253)

Malignant mesothelioma associated with localized myocardial fibrosis: a case report

open access: yesBMC Cardiovascular Disorders, 2021
Left ventricular dysfunction is a common reason for patients’ referral to cardiology departments for examination. Cardiac involvement is one of the possible yet rare presentations of malignant mesothelioma.
Kristyna Vymetalova   +2 more
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

open access: yesAdvanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu   +7 more
wiley   +1 more source

Tumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression

open access: yesAdvanced Science, EarlyView.
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li   +8 more
wiley   +1 more source

Malignant peritoneal mesothelioma

open access: yesSaudi Medical Journal, 2000
Malignant peritoneal mesotheliomas are rare tumors arising from the peritoneal surface. We report a 53 year old, non-asbestos exposed Saudi male who presented with exudative ascites. The diagnosis was obtained from laparoscopic biopsy. To the best of our knowledge this entity has not been described in the Saudi community.
S M, Al-Amri   +2 more
openaire   +2 more sources

Advances in Cancer Immunotherapy for Solid Tumors

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz   +1 more
wiley   +1 more source

ARTISTIC: A randomised trial of human papillomavirus (HPV) testing in primary cervical screening [PDF]

open access: yes, 2009
The official published version of the article can be found at the link below.Objectives: Primary cervical screening uses cytology to detect cancer precursor lesions [cervical intraepithelial neoplasia stage 3 or beyond (CIN3+)]. Human papillomavirus (HPV)
ARTISTIC Trial Study Group   +28 more
core   +1 more source

Emerging Therapies for Malignant Mesothelioma

open access: yes, 2020
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject.

core   +2 more sources

Case report: A1159T mutation in malignant peritoneal mesothelioma may be associated with tumor recurrence

open access: yesSAGE Open Medical Case Reports
Malignant peritoneal mesothelioma is an exceedingly rare malignant tumor. Herein, we present a case of malignant peritoneal mesothelioma in a 59-year-old Chinese female patient who was stable after treatment for multiple relapses.
Ying Li   +7 more
doaj   +1 more source

Peritoneal malignant mesothelioma with epithelioid type, demonstrating high serum and ascitic KL-6 levels: immunohistochemical analyses

open access: yesRare Tumors, 2015
We report a case of KL-6 producing peritoneal malignant mesothelioma. A 56-year-old woman was referred to our hospital on November 2005 with severe abdominal distention.
Saifun Nahar   +11 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy